Jim Cramer Says “Own It, Don’t Trade It” as CVS Health Gains Momentum
CVS Health (NYSE:CVS) has gained 21% this year, with a 3% dividend and a 28 P/E ratio. Jim Cramer recommends holding the stock, citing strong leadership and Aetna's performance. Q2 revenue rose 7.3% to $106.1B, adjusted EPS increased to $2.58, and guidance was raised for 2026. Management expects continued momentum in Aetna's margin recovery but notes risks like Caremark membership decline and elevated medical costs.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift could drive short-term buying pressure.
Market read
CVS's strong Q2 performance and raised outlook may attract investors seeking stable health care exposure.
What to watch
Potential headwinds from 340B pricing pressure and Caremark membership decline in 2027.
Background
Jim Cramer reiterated bullish stance on CVS following its earnings beat and guidance raise.
Ticker impact
CVS reported Q2 results with revenue $106.1B and raised FY2026 EPS guidance to $7.90-$8.10.
Potential upside of 3-5% over the next weeks.
Guidance increase and solid earnings beat indicate improved profitability and cash flow.
Market effects
Positive for health care benefits and pharmacy sectors.
U.S. health care stocks may see modest gains.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
Higher guidance may already be priced in; risk of margin pressure from medical cost trends.
Key entities
- personJim Cramer
Host of Mad Money, provided bullish commentary.
